PriceTargets.com logo

IVERIC bio - ISEE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$39.95 As of 07/11/2023 01:00 AM ET
+0 (0.00%)
Get New IVERIC bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ISEE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ISEE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for IVERIC bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $39.95.

This chart shows the closing price for ISEE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 8 polled investment analysts is to hold stock in IVERIC bio. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/5/2023Stifel NicolausDowngradeBuy ➝ HoldLow
5/4/2023Robert W. BairdDowngradeOutperform ➝ NeutralLow
5/3/2023UBS GroupDowngradeBuy ➝ NeutralN/A
5/2/2023HC WainwrightDowngradeBuy ➝ NeutralLow
5/1/2023Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
5/1/2023Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
5/1/2023WedbushDowngradeOutperform ➝ NeutralLow
5/1/2023GuggenheimDowngradeBuy ➝ NeutralLow
4/3/2023WedbushReiterated RatingOutperform$29.00Low
3/2/2023HC WainwrightReiterated RatingBuy$35.00Low
2/21/2023B. RileyBoost TargetNeutral$17.00 ➝ $19.00Low
2/17/2023HC WainwrightReiterated RatingBuy$35.00N/A
11/10/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$30.00 ➝ $20.00Low
11/4/2022HC WainwrightBoost TargetBuy$26.00 ➝ $35.00Low
10/17/2022B. RileyUpgradeSell ➝ NeutralLow
9/8/2022Stifel NicolausBoost TargetBuy$28.00 ➝ $35.00Low
9/7/2022GuggenheimBoost TargetBuy$30.00 ➝ $35.00Low
9/7/2022Robert W. BairdBoost TargetOutperform$27.00 ➝ $34.00Low
9/6/2022Credit Suisse GroupBoost Target$27.00Low
9/6/2022B. RileyDowngradeNeutral ➝ Sell$12.00 ➝ $8.00Low
8/2/2022UBS GroupInitiated CoverageBuy$20.00Low
7/7/2022Morgan StanleyBoost TargetOverweight$25.00 ➝ $30.00N/A
6/8/2022GuggenheimInitiated CoverageBuy$30.00High
6/8/2022Bank of AmericaInitiated CoverageBuy$18.00Medium
5/20/2022Credit Suisse GroupBoost Target$24.00High
5/12/2022B. RileyInitiated CoverageNeutral$12.00Medium
5/4/2022Stifel NicolausBoost Target$22.00 ➝ $28.00High
3/22/2022Jefferies Financial GroupInitiated CoverageBuy$27.00High
3/3/2022Robert W. BairdInitiated CoverageOutperform$27.00High
2/7/2022Morgan StanleyInitiated CoverageOverweight$25.00High
11/10/2021HC WainwrightBoost TargetBuy$20.00 ➝ $26.00High
9/13/2021HC WainwrightReiterated RatingBuy$20.00High
9/10/2021Credit Suisse GroupBoost TargetOutperform$15.00 ➝ $18.00High
9/10/2021Stifel NicolausInitiated CoverageBuy$22.00High
9/1/2021HC WainwrightReiterated RatingBuy$20.00Medium
8/19/2021HC WainwrightInitiated CoverageBuy$20.00High
7/6/2021Credit Suisse GroupBoost TargetPositive ➝ Outperform$14.00 ➝ $16.00High
8/13/2020Credit Suisse GroupInitiated CoverageOutperform$13.00High
5/25/2020WedbushReiterated RatingOutperform ➝ Market Perform$13.00Low
1/24/2020CowenInitiated CoverageOutperformLow
1/6/2020WedbushInitiated CoverageOutperformMedium
9/18/2019Chardan CapitalReiterated RatingHold$1.25Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
IVERIC bio logo
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.
Read More

Today's Range

Now: $39.95
Low: $39.95
High: $39.95

50 Day Range

MA: $38.88
Low: $36.90
High: $39.95

52 Week Range

Now: $39.95
Low: $9.39
High: $39.99

Volume

N/A

Average Volume

3,616,141 shs

Market Capitalization

$5.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of IVERIC bio?

The following Wall Street analysts have issued research reports on IVERIC bio in the last twelve months: Credit Suisse Group AG, Guggenheim, HC Wainwright, Morgan Stanley, Robert W. Baird, Stifel Nicolaus, StockNews.com, UBS Group AG, and Wedbush.
View the latest analyst ratings for ISEE.

What is the current price target for IVERIC bio?

0 Wall Street analysts have set twelve-month price targets for IVERIC bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for IVERIC bio in the next year.
View the latest price targets for ISEE.

What is the current consensus analyst rating for IVERIC bio?

IVERIC bio currently has 8 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ISEE, but not buy more shares or sell existing shares.
View the latest ratings for ISEE.

What other companies compete with IVERIC bio?

Other companies that are similar to IVERIC bio include RayzeBio, Crinetics Pharmaceuticals, ImmunoGen, Roivant Sciences and Option Care Health. Learn More about companies similar to IVERIC bio.

How do I contact IVERIC bio's investor relations team?

IVERIC bio's physical mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The company's listed phone number is (609) 474-6755 and its investor relations email address is [email protected]. The official website for IVERIC bio is ivericbio.com. Learn More about contacing IVERIC bio investor relations.